Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
Sponsor: University of Texas Southwestern Medical Center
Summary
The purpose of the study is to provide immunosuppression weaning and/or monitoring for an additional 12-months to evaluate the safety and efficacy of belatacept monotherapy in patients previously enrolled in the clinical trial: "Use of donor derived-cell free DNA (AlloSure) and gene expression profiling (AlloMap Kidney) to facilitate Belatacept monotherapy in kidney transplant patients."
Official title: An Extension Protocol for Subjects Previously Enrolled in the "Use of Donor Derived-cell Free DNA (AlloSure) and Gene Expression Profiling (AlloMap Kidney) to Facilitate Belatacept Monotherapy in Kidney Transplant Patients"
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2024-06-14
Completion Date
2026-12
Last Updated
2025-07-14
Healthy Volunteers
No
Conditions
Interventions
Allosure and TruGraf
Precision medicine will be employed to withdraw immunosuppression in kidney transplant recipients.
Immunosuppression Taper
An immunosuppression taper will be employed over a 12-month period for those that are deemed immune quiescent.
Locations (1)
University of Texas Southwestern Medical Center
Dallas, Texas, United States